

Notice of Allowability

Application No.

10/067,190

Examiner

Richard L. Raymond

Applicant(s)

SHIOKAWA ET AL.

Art Unit

1624

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. ☒ This communication is responsive to the Amendment of May 10, 2005.
2. ☒ The allowed claim(s) is/are 1-5 and 7-9.
3. ☐ The drawings filed on _____ are accepted by the Examiner.
4. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some* c) ☐ None of the:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

* Certified copies not received: _____.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.

THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

5. ☐ A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
6. ☐ CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
- (a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached
- 1) ☐ hereto or 2) ☐ to Paper No./Mail Date _____.
- (b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date _____.
- Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).
7. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

1. ☐ Notice of References Cited (PTO-892)
2. ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
3. ☐ Information Disclosure Statements (PTO-1449 or PTO/SB/08), Paper No./Mail Date _____
4. ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material
5. ☐ Notice of Informal Patent Application (PTO-152)
6. ☒ Interview Summary (PTO-413), Paper No./Mail Date 6/22/05
7. ☒ Examiner's Amendment/Comment
8. ☐ Examiner's Statement of Reasons for Allowance
9. ☐ Other _____


Art Unit: 1624

EXAMINER'S AMENDMENT

1. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee. Authorization for this examiner's amendment was given in a telephone interview with Kurt G. Briscoe on June 22, 2005.

2. The application has been amended as follows: Claims 1, 2 and 9 have been rewritten in proper reissue form (underlining and brackets to show the changes from the original claim) and incorporating the Certificate of Correction change to claim 2 as follows:


1. A heterocyclic compound of the formula



wherein

R¹ represents a hydrogen atom or a methyl group,
A represents an ethylene group which may be substituted by methyl.

X represents an oxygen or sulfur atom or the group



in which R² represents a hydrogen atom, a C₁-C₄ alkyl group which may be substituted by a substituent selected from halogens, C₁-C₄ alkoxy groups, C₁-C₄ alkylthio groups and cyano, a C₂-C₄ alkenyl group, a C₂-C₄ alkynyl group, a pyridylmethyl group which may be substituted by halogen and/or methyl, a benzyl group which may be substituted by halogen and/or methyl, a formyl group, an alkylcarbonyl group having 1 to 2 carbon atoms in the alkyl moiety which may be substituted by halogen, a phenylcarbonyl group which may be substituted by halogen and/or methyl, an alkoxy or alkylthiocarbonyl group having 1 to 4 carbon atoms in the alkyl moiety, a phenoxycarbonyl group, a C₁-C₄ alkylsulfonyl group which may be substituted by halogen or a phenylsulfonyl group which may be substituted by methyl,

[R³ represents a hydrogen atom or a C₁-C₇ alkyl group] and

Z represents a 3-pyridyl group or a 4-pyridyl group optionally substituted by at least one substituent selected from halogen atoms, alkyl groups having 1 to 4 carbon atoms, alkoxy groups having 1 to 4 carbon atoms, alkylthio groups having 1 to 4 carbon atoms, haloalkyl groups having 1 to 4 carbon atoms, haloalkoxy groups having 1 to 4 carbon atoms, alkylsulfonyl groups having 1 to 4 carbon atoms, a cyano group and a nitro group.

Art Unit: 1624

2. A compound according to claim 1, wherein

R^1 represents a hydrogen atom,

A represents an ethylene group,

X represents a sulfur atom or the group



and

Z represents a 3-pyridyl group or a 4-pyridyl group optionally substituted by at least one substituent selected from a [fluorine] fluorine atom, a chlorine atom, a bromine atom, a methyl group, a methoxy group, a methylthio group, a trifluoromethyl group, a trifluoromethoxy group, a methylsulfonyl group, a cyano group and a nitro group.

9. The method according to claim 8, wherein such compound is

1-(2-chloro-5-pyridylmethyl)-2-cyanoiminoimidazolidine,

1-(2-fluoro-5-pyridylmethyl)-2-cyanoiminoimidazolidine,

[1-(2-chloro-5-pyridylmethyl)-2-cyanoiminotetrahydropyrimidine,] OR

1-(2-methyl-5-pyridylmethyl)-2-cyanoiminoimidazolidine,

[1-(2-chloro-5-thiazolylmethyl)-2-cyanoiminoimidazolidine,

[1-(2-chloro-5-thiazolylmethyl)-2-cyanoiminotetrahydropyrimidine,

[1-(2-methyl-5-pyrazinylmethyl)-2-cyanoiminoimidazolidine,

[1-(2-chloro-5-pyridylmethyl)-2-cyanoiminothiazolidine,

1-(2-chloro-5-pyridylmethyl)-2-cyanoiminotetrahydro-2H-1,3-thiazine

1-(2-chloro-5-thiazolylmethyl)-2-cyanoiminothiazolidine,

1-(2-methyl-5-pyrazinylmethyl)-2-cyanoiminothiazolidine,

1-(2-methyl-5-thiazolylmethyl)-2-cyanoiminothiazolidine, or

1-(1,2,3-thiaziazol-3-ylmethyl)-2-cyanoiminothiazolidine.]

And, in the specification, column 7, line 16, the amendment intended for line 18, "[Isopoda] Diplododa"


has been rewritten as -- Isopoda --.

Art Unit: 1624

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Richard L. Raymond whose telephone number is (571) 272-0673. The examiner can normally be reached on Monday-Thursday, 10:00 AM-8:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James O. Wilson can be reached on (571) 272-0661. The fax phone number for the organization where this application or proceeding is assigned is (571) 273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).


Richard L. Raymond
Primary Examiner
Art Unit 1624

rr
June 22, 2005